"The EPA is under a Federal Court order mandating sub-24 hour testing results for multiple microorganisms in beach waters by the year 2012."
Nanologix most likely has the cheapest, fastest technology and with ongoing research via the CRADA may be able to improve upon that technology.
So, if Nanologix would also have the go to test for water--- what is the potential market for this area which I am assuming will expand due to the federal mandate? (Please include said expansion in your estimate).
I am wishing for coverage inside the magazine. This is just on their website, not that that's meaningless, but I'd like to open Advance magazine one day and see a story about Nanologix. That's all I was saying.
most likely your dreaming or just a dummy, were not growing cultures at the beach were taking water and putting it under microscopes, bio 101 comon bro get with the program, whens the last time you grew a saltwater culture.. sheesh
Yes, I know. I am just trying to figure out the size of the market for the testing per this old statement:
HUBBARD, OH -- (Marketwire) -- 07/28/09 -- The company (PINKSHEETS: NNLX), following meetings in 2008 and 2009 with the US Environmental Protection Agency, has developed a test kit utilizing BNP(TM) technology for the rapid testing of water samples for specific strains of e-coli bacteria. The EPA is under a Federal Court order mandating sub-24 hour testing results for multiple microorganisms in beach waters by the year 2012.
During ongoing work on development of the water-quality testing kit for the EPA, recent company research has indicated that NanoLogix's BNP(TM) and BNC(TM) test kits may be used for detection and identification of viruses when combined with antibody-coated magnetic particles. This is potentially a major breakthrough for the company's diagnostic technology, adding significantly to the battery of detection capabilities currently available with BNP and BNC technology by moving beyond bacterial, spore and mold detection to include the realm of viruses. NanoLogix plans to contract with an Ohio-based research center with BSL-3 virology capabilities to perform further research on the efficacy of this approach.